Safety study of Breztri aerosphere in Indian COPD patients
Part of Lungs & breathing clinical trials.
This study tests a medication called Breztri aerosphere (a triple-combination inhaler) to see how safe and well-tolerated it is in Indian patients with COPD who have had recent flare-ups. It may help people who need better control of their breathing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with COPD by a doctor.
- You have had at least one severe flare-up or two moderate flare-ups in the past year.
- Your lung function (FEV1) is between 30% and 80% of the normal predicted value.
- If you are a woman who can still have children, you must use effective birth control and have a negative pregnancy test.
- You are not currently taking part in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study tracks how well and safely Breztri (a combination inhaler medicine) works in people with COPD (a chronic lung disease) when used in real-world settings in Korea. The goal is to make sure the drug continues to be safe and effective for patients using it as prescribed.
This trial tests a once-daily inhaler that combines a long-acting bronchodilator with a corticosteroid to see if it improves breathing, lung function, and quality of life in people with moderate-to-severe COPD who have significant shortness of breath.
This study tests whether a new approach can help relieve severe shortness of breath in people with COPD who are already on standard inhaler therapy. It may help you breathe easier and improve your daily life.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
Hear when a new Moderate to Severe COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.